- Not designed to predict need for admission or surgical therapy
- However, an endoscopic score of 0 is associated with lower risk of colectomy compared to higher scores. (Manginot 2016)
If endoscopic data are not available, the modified Mayo score performs equally well. (Lewis 2008)
Addition of the selected points.
Facts & Figures
|1–2 stools/day more than normal||+1|
|3–4 stools/day more than normal||+2|
|>4 stools/day more than normal||+3|
|Visible blood with stool less than half the time||+1|
|Visible blood with stool half of the time or more||+2|
|Passing blood alone||+3|
|Mucosal appearance at endoscopy|
|Normal or inactive disease||0|
|Mild disease (erythema, decreased vascular pattern, mild friability)||+1|
|Moderate disease (marked erythema, absent vascular pattern, friability, erosions)||+2|
|Severe disease (spontaneous bleeding, ulceration)||+3|
|Physician rating of disease activity|
*Assigning a score of 3 requires patients to have ≥50% of bowel movement accompanied by visible blood and 1+ bowel movement with blood alone.
- The higher the score, the more severe the case of ulcerative colitis.
- The highest score possible is a 12.
- Scores should be compared to previous scores taken for a patient.
- The mucosal appearance at endoscopy is not included in the Partial Mayo Score.
- The Mayo score was described by Schroeder et al. in 1987 as a means of assessing response to pH dependent 5-ASA therapy (Asacol) in a randomized that included 87 patients. It was designed to be simple to calculate at the bedside but does include endoscopic findings.
- The Mayo score remains unvalidated but correlates closely with quality of life. (Irvine 1994)
- Numerous other scoring systems for UC disease severity exist and some have been validated. (Travis 2013)
- Despite lack of formal validation, the Mayo Score remains a common assessment tool for ulcerative colitis in current research. (Sandborn 2016)
Original/Primary ReferenceSchroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987 Dec 24;317(26):1625-9. PMID: 3317057.
ValidationTravis SPL, et. al. Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of Severity. Gastroenterology. 2013;145:987–995.
Other ReferencesLewis JD, et. al. Use of the Non-invasive Components of the Mayo Score to Assess Clinical Response in Ulcerative Colitis. Inflamm Bowel Dis. Dec 2008; 14(12): 1660–1666. doi: 10.1002/ibd.20520.Sutherland LR, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 92.6; 1987: 1894-1898.Paine ER. Colonoscopic evaluation in ulcerative colitis. Gastroenterology report 2.3; 2014: 161-168.D’Haens G, et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 132.2; 2007: 763-786.Manginot C et al. An endoscopic Mayo score of 0 is associated with a lower risk of colectomy than a score of 1 in ulcerative colitis. Gut 64.7; 2015: 1181.Irvine EJ, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 106.2; 1994: 287-296.Sandborn WJ, et al. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. New England Journal of Medicine 374.18; 2016: 1754-1762.
About the Creator
Kenneth W. Schroeder, MD, is an associate professor of medicine, specifically in gastroenterology and hepatology the Mayo Clinic. Dr. Schroeder researches endoscopic diagnosis/treatment of GI diseases and inflammatory bowel disease.
To view Dr. Kenneth W. Schroeder's publications, visit PubMed